FILE – This December 2022 image provided by Eisai shows vials and packaging for their medication Leqembi. The first drug shown to slow Alzheimer’s disease hit the U.S. market in 2023, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. (Eisai via AP, File)